Bris­tol My­er­s' block­buster-to-be Re­blozyl scores a PhI­II win

Bris­tol My­ers Squibb un­veiled a sur­prise vic­to­ry on Mon­day for its po­ten­tial $4 bil­lion-per-year drug Re­blozyl, with the bio­phar­ma an­nounc­ing that it hit a pri­ma­ry end­point for a Phase III tri­al.

The pos­i­tive re­sult, de­fined as a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment” in red blood cell trans­fu­sion in­de­pen­dence (RBC-TI), or how long a pa­tient with ane­mia goes with­out a trans­fu­sion, with in­creas­ing lev­els of he­mo­glo­bin in­creas­ing in pa­tients who re­quire red blood cell trans­fu­sions, fol­lows FDA push­back on a third ap­proval in March.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER